Australia’s most read investor-focused magazine for ASX-listed Tech & Biotech stocks

Memphasys has taken another step towards turning its Felix sperm-selection technology into a recurring commercial business, securing an exclusive distribution agreement with Warsaw-based TK Biotech.

The deal carries a minimum contracted value of about €212,000, equivalent to roughly A$350,000, across a two-year commercial term. Poland becomes the third European market where Felix has achieved sales or a commercial agreement, following Italy and the United Kingdom.

For investors, the dollar figure is modest in isolation. The more important feature is the structure. Rather than relying on a one-off equipment sale, the agreement is intended to progress from evaluation and clinic demonstrations into recurring quarterly purchases.

That is the commercial model Memphasys needs to prove if Felix is to develop from an interesting reproductive technology into a scalable medical-device platform.

Evaluation first, recurring orders next

TK Biotech will begin with a three-month evaluation and market-introduction period covering product training, demonstrations and early engagement with Polish fertility clinics.

The initial evaluation order is expected to be invoiced during the September 2026 quarter. Assuming the evaluation phase is completed, minimum quarterly purchase commitments are scheduled to begin in the December 2026 quarter and increase materially during the second year.

Revenue will be recognised when products are supplied and invoiced, while cash receipts will depend on the agreed payment terms. That distinction matters because the A$350,000 headline value is not immediate revenue or cash in the bank. It is the minimum contracted value over the commercial term, subject to the agreement progressing through its planned stages.

Exclusivity is also conditional. TK Biotech retains exclusive Polish rights only while meeting its minimum purchasing, regulatory, commercial and market-development obligations. Performance incentives are included to encourage sales above the contracted floor.

This provides Memphasys with some protection against a distributor securing a territory and then leaving Felix to gather dust in the catalogue.

Poland offers a supportive IVF backdrop

The timing is helped by Poland's expanding publicly funded IVF program, introduced in June 2024.

By 31 May 2026, the program was operating through 58 fertility clinics, had qualified more than 51,000 couples and had contributed to 29,806 clinical pregnancies and 15,000 births.

Greater public funding does not automatically translate into Felix sales, but it expands the addressable clinical environment. More treatment cycles can increase demand for technologies that improve laboratory workflows, standardise processes and potentially support better clinical outcomes.

Felix uses electrophoresis and size-exclusion membranes to isolate viable sperm cells without traditional centrifugation. Memphasys says the process is fast, gentle and standardised, while reducing laboratory time and avoiding some of the cellular stress and DNA damage associated with centrifugation.

The investment case still depends on clinics accepting those benefits in practice and purchasing enough cartridges to create repeat revenue.

Local partner brings established clinic relationships

TK Biotech appears to offer more than a sales address and a phone number.

Established in 2001, the company distributes laboratory equipment, diagnostic products and reagents across IVF, diagnostics, life sciences, biotechnology, veterinary medicine and pharmaceuticals. It has a dedicated IVF operation, scientific specialists and technical-service coverage across major Polish cities.

Under the partnership model, TK Biotech will manage local clinic relationships, demonstrations, customer onboarding, training and first-line support. Memphasys will provide technical assistance, approved marketing material and participation in selected clinic meetings, seminars and conferences.

That division of labour reduces the need for Memphasys to build a large direct sales operation in every market. It also places execution in the hands of a distributor that already understands the local IVF sector.

Director of Clinical Partnerships and Growth, Associate Professor Hassan Bakos, said Poland provided a clear pathway from evaluation to recurring quarterly orders. He added that the opportunity originated from direct interest by TK Biotech and progressed rapidly following meetings at the ESHRE conference in London.

TK Biotech Sales Director IVF Anna Maria Pawlak said Felix complemented the distributor's existing portfolio and addressed an important clinical need in Polish IVF laboratories.

European pipeline begins to take shape

Memphasys is also appointing a Director of Commercial Operations - Europe, expected to start in mid-September 2026. The role will support partner onboarding, clinic conversion, key-account management and the eventual development of a broader European team.

The company says it is progressing additional discussions with prospective partners and IVF groups following ESHRE 2026.

Investors should now watch the conversion points rather than the size of the pipeline alone: the September evaluation order, the first minimum quarterly order expected in the December quarter, and evidence that cartridge purchases rise during the second year.

Poland adds another pin to the European map. The next challenge is ensuring those pins produce repeat orders rather than merely decorating the corporate presentation.

Adisyn has cleared an important technical hurdle in its effort to develop graphene materials for next-generation semiconductors, successfully depositing graphene across a 200mm copper wafer at temperatures below 300 degrees Celsius.

The achievement matters because semiconductor technologies are ultimately judged not by what they can do on a thumbnail-sized laboratory sample, but by whether they can be scaled to the wafer formats used by industry.

Adisyn’s previous result involved a 1cm² coupon. The latest wafer has a surface area of about 314cm², representing roughly 300 times the area coated in the earlier process run. Management says the result arrived several months ahead of its internal expectations.

That is genuine technical progress. It does not yet amount to a commercially qualified manufacturing process, but it moves the program beyond the small-sample stage where many promising materials technologies spend their days gathering dust and academic citations.

Independent testing provides an early validation point

Following deposition, 12 locations were selected across the wafer’s four quadrants and at different distances from the centre. Each location was measured five times using Raman spectroscopy, while samples from all 12 locations were also examined using transmission electron microscopy at the Hebrew University of Jerusalem.

Graphene was identified at every sampled location. The distribution of the test points is important because it suggests the material was not confined to one favourable section of the wafer.

Managing director Arye Kohavi described the result as a “huge step forward”, adding that identifying graphene at all 12 independently tested locations provided validation of the company’s technology and development approach.

Investors should nevertheless keep the distinction between sampled coverage and fully characterised manufacturing uniformity firmly in mind. Twelve successful locations provide encouraging evidence across the wafer, but semiconductor production requires detailed control over thickness, defects, repeatability and performance from run to run. Adisyn has identified those areas as priorities for the next phase of work.

Why low-temperature graphene is the prize

Adisyn is developing a low-temperature atomic layer deposition process intended to grow graphene directly on semiconductor wafers.

The temperature component is critical. Semiconductor devices contain multiple materials and delicate structures that can be damaged or altered by excessive heat during later manufacturing stages. A process operating below 300 degrees Celsius may therefore be more compatible with existing semiconductor fabrication flows than conventional high-temperature graphene growth methods.

The broader commercial target is the performance of interconnects, the tiny conductive pathways carrying electrical signals within chips. As device features become smaller, traditional copper interconnects face increasing resistance, heat and reliability constraints.

Graphene is being studied internationally because of its electrical and thermal properties, including its potential use in hybrid graphene-metal structures. The applications highlighted by Adisyn include artificial intelligence processors, high-performance computing and memory devices, all markets where heat management and data movement are increasingly becoming limiting factors.

The next hurdle is 300mm

A 200mm wafer is a recognised industrial format and remains widely used across semiconductor manufacturing. However, the most advanced processors and memory products are predominantly manufactured on 300mm wafers.

Adisyn sees the 200mm result as a pathfinder towards that larger format. Scaling from 200mm to 300mm is not simply a matter of buying a bigger dinner plate. The surface area increases materially, placing greater demands on gas flow, temperature consistency, deposition uniformity and defect control.

Before that leap becomes commercially meaningful, the company intends to repeat and refine the 200mm process, assess uniformity and defectivity, collect initial reliability data and begin device-integration work.

Commercial potential remains prospective

The result gives Adisyn a stronger technical basis for approaching semiconductor manufacturers and pursuing joint-development programs. Potential business models could include licensing, process partnerships, materials supply or collaborative development.

None of those pathways has yet translated into forecast revenue or earnings. Customer qualification in the semiconductor industry can be painstakingly slow, while new materials must prove they can deliver repeatable performance without disrupting established production economics.

For investors, the significance is therefore best viewed as risk reduction rather than commercial validation. Adisyn has demonstrated a substantial increase in scale and obtained independent evidence of graphene at geographically dispersed locations across an industry-standard wafer.

The next value-creating milestones will be repeatability, quantified uniformity, device performance, customer engagement and progress towards 300mm wafers. The science has moved forward impressively. The business case now needs to catch up.

Metallium has secured the first commercial monetisation agreement for its proprietary Flash Joule Heating platform, turning years of reactor development and engineering work into contracted service revenue.

The 12-month technology services agreement with Environmental Clean Technologies will evaluate whether Flash Joule Heating, combined with chlorine, can offer a faster and more scalable route to manufacturing MXenes than conventional hydrofluoric acid-based processing.

Metallium will provide access to its reactor systems, engineering expertise and Gator Point Technology Campus in Texas. Environmental Clean Technologies brings exclusive commercial rights to use Flash Joule Heating for MXene production, but does not currently possess a working reactor platform of its own. The partnership therefore marries intellectual property rights with Metallium’s physical infrastructure and operating know-how.

For investors, the significance extends beyond the immediate revenue. This is the first test of Metallium’s proposed Processing-as-a-Service model, which sits alongside its core strategy of building and operating facilities that recover critical and precious metals.

US$1.4 million Phase 1 package

Metallium can receive up to US$1.4 million, or about A$2 million at the exchange rate used by the company, during the initial 12-month program.

Of that amount, US$500,000 is payable unconditionally upon execution. The remaining US$900,000 is structured as four quarterly payments of US$225,000, beginning on 1 November 2026.

The agreement also includes 20 million Environmental Clean Technologies options with an exercise price of A$0.18 and a 12-month expiry. Those options remain subject to shareholder approval and have not been assigned any value in Metallium’s calculation of the transaction consideration.

The exercise price represents a roughly 33 per cent premium to Environmental Clean Technologies’ last traded price of A$0.135 before its shares were suspended pending details of the proposed MXene transaction. That makes the equity component prospective rather than immediately valuable. It could provide upside if the MXene program succeeds, but investors should treat it separately from the contracted cash payments.

There is another wrinkle worth noting. The agreement may be terminated by either party with 90 days’ written notice, or following material breach or insolvency. While the upfront payment is unconditional, the description of total cash consideration as “up to” US$1.4 million is therefore important.

Keeping control of the reactor intellectual property

Metallium retains ownership of its existing reactor technology and future improvements covering reactor systems, engineering developments, process enhancements and related technical advances.

Environmental Clean Technologies will own the MXene material produced during the research program, while protections are included to prevent reverse engineering, replication and unauthorised use of Metallium’s platform.

That division is commercially important. Metallium is being paid to provide technology access and engineering support without surrendering the underlying reactor intellectual property. If the model works, it could potentially be repeated with other partners and applications.

The longer-term prize would be a commercial licence and royalty agreement following successful completion of the research program. The parties have agreed to negotiate such an arrangement in good faith, but neither is obliged to enter one. Phase 2 should therefore be viewed as an opportunity rather than contracted revenue.

Why MXenes matter

MXenes are atomically thin materials produced by selectively removing one layer from ceramic precursors known as MAX phases. Their combination of electrical conductivity, high surface area, flexible structure and tuneable surface chemistry has attracted interest across defence materials, electromagnetic interference shielding, electronics, sensors, water treatment and energy storage.

The commercial bottleneck is manufacturing. Traditional production commonly relies on hydrofluoric acid etching, a process described as hazardous, slow, expensive and difficult to scale.

The proposed alternative uses rapid heating in the presence of chlorine to remove the unwanted layer as volatile metal chlorides. The theory is appealing, but the commercial efficiency, scalability, product quality and economics still need to be demonstrated through testing.

This distinction matters. Metallium has secured a paying customer for access to its platform, not yet proven that Flash Joule Heating can manufacture MXenes economically at commercial scale.

More than a one-off services contract

Management is positioning the agreement as a template for capital-light revenue streams including engineering services, equipment supply, operator support, technology licences, processing fees and royalties.

That would complement the company’s Build, Own and Operate strategy, where Metallium carries more capital and operating responsibility but retains the economics from recovered metals.

The immediate financial contribution is relatively modest compared with the ambitions of a commercial processing network. Its strategic value, however, lies in external validation. A third party is paying to use Metallium’s reactors, facilities and technical expertise.

The next questions are whether the research program produces technically competitive MXenes, whether all scheduled payments are received, and whether the relationship advances into a binding licence or royalty arrangement. For now, Metallium has moved its platform technology from promise to paid commercial engagement - an encouraging first step, albeit well before the finish line.

Audeara has crossed an important commercial threshold, with two customer product programs under its chip-level artificial intelligence audio partnership with Optek Microelectronics entering production.

The company has received initial purchase orders worth about A$31,000 across the two programs. That amount will not transform the balance sheet, and management has been appropriately clear that the orders are not financially material on their own. The more significant development is that Audeara’s technology has progressed through development, technical validation, customer acceptance and into revenue-generating production.

For investors, this shifts the Optek relationship from a promising technology collaboration to a functioning commercial arrangement. Audeara is now being paid when approved production units incorporating its proprietary AI audio technology are manufactured.

That distinction matters. Plenty of small technology companies can demonstrate clever software in controlled conditions. Far fewer can integrate their intellectual property into a third-party semiconductor platform, satisfy both the chip supplier and end customer, and emerge with a production order.

A capital-light model begins to take shape

Audeara’s licensing model is based on a fee for each chip containing its approved technology. The exact licence fee has not been disclosed because the commercial terms are considered sensitive.

The attraction of this model is its potential operating leverage. Audeara does not need to manufacture the semiconductor, own a fabrication plant or finance large inventories. Its task is to develop, optimise and license the algorithms. If customers increase production volumes, licensing revenue can rise without Audeara carrying the same capital burden as a conventional hardware manufacturer.

The first A$31,000 therefore should be viewed as evidence that the payment mechanism works, rather than evidence that meaningful scale has already arrived. Future revenue will depend on additional orders being placed and units being manufactured under approved customer programs. No production volumes, minimum commitments or forward revenue expectations were provided, leaving investors without enough information to estimate the near-term earnings contribution.

That uncertainty is the chief caveat. A scalable model is not the same as a scaled business. Audeara has opened the toll booth, but the number of vehicles passing through remains unknown.

Why putting AI directly on the chip matters

The commercial programs include Audeara’s AI noise-reduction technology deployed directly on the semiconductor platform. On-chip processing can be valuable in audio products because it supports low latency, efficient use of limited processing resources and improved speech and sound performance.

Audeara believes this capability could have broader applications across consumer audio, hearables, assistive-listening products and hearing aids. Noise reduction and speech enhancement are especially relevant in products where clarity, responsiveness and power efficiency are critical.

Chief executive James Fielding said the deployment demonstrated that Audeara could adapt existing silicon and extract more capability from a semiconductor platform.

“This first deployment validates both our capital light licensing strategy and proves a pathway for our technology to be deployed efficiently and at scale,” he said.

The emphasis on existing silicon is commercially sensible. Designing a new chip from scratch can be expensive and time-consuming. Software that improves the performance of established platforms may offer customers a faster route to product differentiation, provided the technology performs reliably and can be integrated without excessive development work.

Optek provides a route into global audio supply chains

Optek brings more than 20 years of experience in professional audio digital signal processing and system-on-chip design. Its chipsets are used across consumer electronics, professional audio and new-energy vehicles, while its website identifies relationships with a range of internationally recognised electronics brands.

That industry reach gives Audeara exposure to markets beyond its traditional hearing-health products. However, the presence of large brands within Optek’s broader customer network should not be interpreted as confirmation that any particular brand is using Audeara’s technology. The two commercial customer programs have not been identified.

Still, integration with a semiconductor supplier can be strategically valuable because chip platforms may be incorporated into multiple products and customer designs. Successful performance in the first two programs could lower the technical and commercial barriers to further deployments.

The next test is volume

Audeara has established that its AI audio intellectual property can be licensed, embedded on third-party silicon and taken through to commercial production. That is a credible de-risking milestone for a company pursuing a capital-light technology strategy.

The investment case now turns to repetition and scale. Investors will be watching for follow-on orders, additional approved products, new semiconductor partnerships and evidence that fee-per-chip revenue is growing faster than the associated development costs.

For now, the dollars are small but the strategic step is genuine. Audeara has moved from proving that the technology works to proving that somebody will pay for it. The next challenge is proving that many more chips can carry the same tune.

KTEK Aerosystems has entered its first full reporting period as a listed company with a clear investor proposition: use fresh capital to restart deliveries, lift manufacturing capacity and build a broader international defence and aerospace business.

The company raised $10 million through its May 2026 initial public offering at 20 cents per share. Management says the funds are being directed towards working capital, production expansion, international operations and business development.

The near-term investment case, however, rests less on strategic ambition and more on whether KTEK can convert its existing backlog into regular deliveries and customer receipts.

Founder and managing director Dekel Keisar summed up the task neatly: “Our focus is firmly on execution.”

That execution challenge begins with KTEK’s principal production program, where deliveries were interrupted by regional logistics constraints and the timing of export licence approvals. Customer demand is described as strong and the backlog remains intact, but investors will want evidence that orders can move through the factory and into customers’ hands.

September becomes the first major milestone

KTEK is targeting a restart of deliveries during September 2026, subject to several conditions. These include successful qualification of new high-capacity tooling, customer acceptance, component availability and the receipt of required export approvals.

The tooling qualification process is expected to be completed during August. If it clears the necessary hurdles, KTEK intends to increase monthly deliveries aggressively as production ramps.

This is the most important operational marker in the report. A September restart would support revenue conversion, improve cash receipts and demonstrate that the interruption was temporary rather than structural. Any further slippage would place more attention on the company’s cash position and supply-chain dependencies.

Management is also working to convert work-in-progress while preserving the manufacturing value already embedded in those products. That suggests some costs have been incurred ahead of delivery, making the timing of customer acceptance and payment particularly relevant.

United States expansion adds opportunity and complexity

KTEK has advanced plans for a United States assembly and logistics operation. Work completed so far includes facility assessments, local supplier development, planning for assembly and warehousing, export licence applications and engagement with manufacturing partners.

The proposed operation is intended to provide local customer support while creating another delivery pathway from KTEK’s European operations. The company is also preparing a roadmap towards AS9100 aerospace quality certification.

A US presence could improve KTEK’s access to defence programs and strengthen supply-chain resilience, but it also introduces additional costs, certification requirements and regulatory complexity. Investors should distinguish between groundwork and revenue-generating operations. The facility remains under development and no financial contribution has been quantified.

Higher-value manufacturing could lift revenue per program

KTEK secured an additional production order that expands an existing defence program into electro-mechanical assembly. More significantly, the company is discussing a transition to a full turnkey manufacturing model.

Under that structure, KTEK would take responsibility for procurement, supply-chain management, manufacturing and final assembly. This could increase the value of work performed on each program and deepen customer relationships.

The qualification pipeline also includes a Built-to-Spec assessment with a major international defence group, a first quotation for a new defence manufacturing program and a proposed European offset cooperation arrangement.

These opportunities are strategically encouraging, but they remain prospective. No production orders have been received through the supplier qualification process, the new quotation remains under evaluation and the European proposal still requires customer approval.

KTEK has also established a cooperation framework covering advanced aerospace and satellite communications systems. Prototype manufacturing and engineering work may lead to serial production, although there are no committed volumes or minimum revenues.

Cash runway requires a careful reading

KTEK ended June with $4.625 million in cash after receiving the IPO proceeds. Customer receipts were just $273,000, while net operating cash outflow reached $2.399 million. Investing activities consumed another $2.237 million and financing activities generated a net inflow of $9.379 million.

Using the prescribed quarterly cash-flow calculation, KTEK reported funding for 1.9 quarters. Management argues this figure was distorted by non-recurring and timing-related payments, including pre-listing trade creditors and offer costs.

After adjustments, the company estimates its underlying quarterly operating cash requirement at about $800,000 to $1 million. On that basis, cash could cover roughly five quarters even without customer receipts, with the runway expected to improve once deliveries restart.

That explanation is plausible, but the September production target now carries financial as well as operational importance.

The balance sheet also includes $2.239 million of financing facilities, all of which were drawn at quarter-end. There was no confirmed unused facility capacity. Related-party cash flows included $213,000 in directors’ fees and associated corporate services, plus $104,000 in net advances involving Israeli directors and a related party.

Investors now need proof of cadence

KTEK has capital, backlog and several credible pathways to expand its manufacturing role. What it does not yet have is a demonstrated post-listing delivery rhythm.

The next phase will be judged on tooling qualification, export approvals, September shipments, customer receipts and the conversion of proposals into binding orders. The strategy is broad, but the immediate scorecard is refreshingly simple: restart production, deliver consistently and turn backlog into cash.